E.E. Geduld’s Amicus Therapeutics FOLD Stock Holding History

E.E. Geduld’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-10,000	Closed	-$97K	–	182
2015 Q4	$97K	Buy	+10,000	New	+$90.1K	0.06%	113
2015 Q3	–	Sell	-25,000	Closed	-$354K	–	232
2015 Q2	$354K	Buy	25,000 +5,000	+25%	+$60.1K	0.22%	99
2015 Q1	$218K	Buy	+20,000	New	+$176K	0.15%	153

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

E.E. Geduld's FOLD Position: Q1 2016 in Review

E.E. Geduld sold out of Amicus Therapeutics (FOLD) in Q1 2016, closing a stake of 10,000 shares — an estimated $97K sold.

E.E. Geduld first reported a position in FOLD in Q1 2015 and held it in 3 quarters. The position peaked at $354K in Q2 2015. 128 funds tracked by Wall St. Rank hold FOLD as of Q1 2016.

E.E. Geduld reported no remaining Amicus Therapeutics position as of Q1 2016 after selling out during the quarter.
E.E. Geduld sold 10,000 Amicus Therapeutics shares in Q1 2016, an estimated $97K.
E.E. Geduld first reported a position in Amicus Therapeutics in Q1 2015 and held it in 3 quarters.
E.E. Geduld's Amicus Therapeutics position peaked at $354K in Q2 2015.
128 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2016.

Based on E.E. Geduld's 13F filing for Q1 2016, filed 9 May 2016.